Minodronic acid

DB06548InvestigationalSmall molecule

Investigated for use/treatment in multiple myeloma, breast cancer, osteoporosis, and lung cancer.

Mechanism: Pharmacologically active on Farnesyl pyrophosphate synthase and Geranylgeranyl pyrophosphate synthase
Curator reviewed
Primary indication: Investigated for use/treatment in multiple myeloma, breast cancer, osteoporosis, and lung cancer.Curator reviewed
Formula / weight: C₉H₁₂N₂O₇P₂ · 322.1483 g/mol (avg)
Also known as: Minodronate
Code names: ONO-5920 · YM-529

Resolves to

Compound

Structure

InChIKeyVMMKGHQPQIEGSQ-UHFFFAOYSA-NSMILESOC(CC1=CN=C2C=CC=CN12)(P(O)(O)=O)P(O)(O)=O

Targets

What you can answer from here — as of February 21, 2021

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

6Clinical trialsPhase, status and sponsor resolved per trial

10+ReferencesStructured and connected to the statements they support

Which drugs share a target with Minodronic acid, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.